Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Recruiting now · Phase 1/Phase 2

Conditions studied: Lymphoma

In brief

PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.

Key facts

Study ID

NCT06883526

Run by

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

People needed

60

Starts

2025-05-16

Expected to finish

2027-05-01

Last updated by the study team

2026-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fully understand this study and voluntarily sign the ICF；
• Age ≥18 at ICF signing, regardless of gender；
• Histologically confirmed relapsed or refractory lymphoma.

You may not qualify if…

• Lymphoma with known CNS involvement；
• Severe cardiovascular/cerebrovascular diseases.
• Any other reason deeming the participant unsuitable for the study, as judged by the investigator.

Where it is running

• The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.